About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clinical Trials in San Diego | 14,679 Studies Near You | Clareo Health

Clinical Trials LocationsSan Diego

Clinical Trials in San Diego

Discover 14,679 clinical trials near San Diego, California. Find research studies in your area.

Browse by condition:

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma Pancreatic Cancer

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 11941-11960 of 14,679 trials

COMPLETEDPhase 2< 1 mile

OTO-104 for the Treatment of Meniere's Disease

NCT01412177

The purpose of this study is to evaluate the effectiveness of OTO-104 for the treatment of Meniere's disease.

Meniere's Disease

Otonomy, Inc.154 participantsStarted Nov 2013

San Diego, California, United States • Cincinnati, Ohio, United States

COMPLETEDPhase 3< 1 mile

Long Term Study to Evaluate Safety and Efficacy of M518101 in Subjects With Plaque Psoriasis

NCT01908595

This study is to evaluate the efficacy and safety for long term use of M518101 in subjects with plaque psoriasis.

Maruho North America Inc.480 participantsStarted Aug 2013

Mesa, Arizona, United States • Bakersfield, California, United States • Los Angeles, California, United States +28 more locations

Find Trials by Condition in San Diego

Breast Cancerin San Diego Lung Cancerin San Diego Prostate Cancerin San Diego Colorectal Cancerin San Diego Melanomain San Diego Leukemiain San Diego Lymphomain San Diego Pancreatic Cancerin San Diego Ovarian Cancerin San Diego Brain Cancerin San Diego

Data from ClinicalTrials.govTerms

COMPLETEDPhase 2< 1 mile

Study 767905/008 Extension Study: Alvimopan for Treatment of Opioid-Induced Bowel Dysfunction in Cancer Pain Subjects

NCT00135577

Study SB-767905/008 was a multicenter study to evaluate the effectiveness and safety of multiple dosage regimens of an investigational drug for the treatment of constipation due to prescription pain medication in participants with cancer pain. Study ABD101684 will serve as an extension to Study SB-767905/008 and offer continued access to blinded investigational product to participants who have completed the original study. The purpose of Study ABD101684 is to evaluate the safety and efficacy of alvimopan compared to placebo in subjects who completed Study SB-767905/008 and elected to participate in this extension study.

CancerBowel Dysfunction

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)67 participantsStarted Sep 2004

Duarte, California, United States • Fountain Valley, California, United States • La Verne, California, United States +37 more locations

COMPLETEDPhase 2< 1 mile

Effect of Febuxostat on Blood Pressure

NCT01496469

The purpose of this study is to evaluate the effect of febuxostat, once daily (QD), compared to placebo on lowering ambulatory 24-hour mean blood pressure of participants with hypertension and hyperuricemia (not associated with gout).

Takeda121 participantsStarted Feb 2012

Foley, Alabama, United States • Buena Park, California, United States • Carmichael, California, United States +42 more locations

COMPLETEDPhase 2< 1 mile

Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma

NCT01462695

This phase II trial studies how well sunitinib malate works in treating younger patients with recurrent, refractory, or progressive malignant glioma or ependymoma. Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Childhood Cerebellar Anaplastic AstrocytomaChildhood Cerebral Anaplastic AstrocytomaChildhood Cerebral Astrocytoma+8 more

National Cancer Institute (NCI)30 participantsStarted Jan 2012

Birmingham, Alabama, United States • Birmingham, Alabama, United States • Little Rock, Arkansas, United States +93 more locations

COMPLETEDPhase 1< 1 mile

Study of a DNA-based Venezuelan Equine Encephalitis Virus DNA Vaccine Administered by Electroporation in Healthy Volunteers

NCT01984983

The Phase I study will assess the basic safety, tolerability, and immunogenicity of a DNA-based Venezuelan equine encephalitis virus (VEEV)vaccine candidate delivered by electroporation . The study will enroll 40 healthy adult volunteers ages 18-49 and will comprise evaluation of intradermal or intramuscular administration by electroporation. Administration of the vaccine candidate will be at two DNA dose levels (0.5 mg/ml and 2.0 mg/ml) for each route of administration. Electroporation will be administered using the TriGrid Delivery System devices for intramuscular and intradermal delivery. An additional group of subjects will serve as a placebo control, receiving injections of saline with electroporation. The overall goal of this study will be to determine if further human clinical studies of the vaccine candidate are warranted and, if so, to aid in the selection of dose and route of administration for future studies.

Venezuelan Equine Encephalitis Virus Infection

Ichor Medical Systems Incorporated42 participantsStarted Dec 2013

San Diego, California, United States

UNKNOWN< 1 mile

fFN Clinical Evaluation in Asymptomatic Women at High Risk for Preterm Birth

NCT01955148

This study is designed to determine if quantitative analysis of fetal Fibronectin (fFN) can be used to advance prediction of spontaneous preterm birth (sPTB). This will be a prospective observational multi-center study with approximately 15 to 20 US sites, and approximately 1210 subjects evaluating the clinical utility of the Rapid fFN 10Q system for preterm birth risk assessment. A single fFN specimen will be collected from each subject between 16 weeks, 0 days and 21 weeks, 6 days. The primary and secondary maternal outcome measures will be determined based on the date of delivery and the estimated date of confinement (EDC), which will be evaluated in a standardized manner.

Hologic, Inc.1,210 participantsStarted Oct 2013

Birmingham, Alabama, United States • San Diego, California, United States • Newark, Delaware, United States +13 more locations

TERMINATEDPhase 4< 1 mile

Surgical Reduction of the Inferior Turbinates for Nasal Obstruction

NCT00737906

The primary goal of this post-marketing surveillance study is to assess whether surgical turbinate reduction performed using a Coblation® device is associated with reduced nasal obstruction symptoms.

Chronic RhinitisInflammation of the Nasal MucosaInflammation of Nasal Tissue

ArthroCare Corporation30 participantsStarted Oct 2007

San Diego, California, United States • Aurora, Colorado, United States • Boynton Beach, Florida, United States +2 more locations

COMPLETEDPhase 311 miles

A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation

NCT01807923

The primary objective of the study was to evaluate the efficacy of lumacaftor in combination with ivacaftor at Week 24 in participants aged 12 years and older with cystic fibrosis (CF) who are homozygous for the F508del mutation on the CF transmembrane conductance regulator (CFTR) gene.

Cystic Fibrosis, Homozygous for the F508del CFTR Mutation

Vertex Pharmaceuticals Incorporated559 participantsStarted May 2013

Birmingham, Alabama, United States • Anchorage, Alaska, United States • Tucson, Arizona, United States +86 more locations

COMPLETEDPhase 111 miles

Safety Study of Attenuated Vaccinia Virus (GL-ONC1)With Combination Therapy in Head & Neck Cancer

NCT01584284

The purpose of this study is to determine the safety and tolerability of GL-ONC1 administered intravenously in combination with radiation therapy and cisplatin (CDDP)in patients with locoregionally advanced head and neck cancer.

Cancer of Head and Neck

Genelux Corporation19 participantsStarted Apr 2012

La Jolla, California, United States

COMPLETEDPhase 365 miles

Study of the Efficacy and Safety of Alirocumab (REGN727/SAR236553) in Combination With Other Lipid-modifying Treatment (LMT) (ODYSSEY OPTIONS I)

NCT01730040

This is a randomized, double-blind, active-comparator, parallel-group study in patients at high cardiovascular risk with nonfamilial hypercholesterolemia or heterozygous familial hypercholesterolemia (heFH).

Hypercholesterolemia

Regeneron Pharmaceuticals355 participantsStarted Oct 2012

Mobile, Alabama, United States • Chandler, Arizona, United States • Tucson, Arizona, United States +94 more locations

COMPLETEDPhase 384 miles

Gadobutrol Enhanced MRA of the Renal Arteries

NCT01344460

Subjects referred for a routine CTA (computed tomography angiography) or MRA (magnetic resonance angiography) will be invited to participate in the study and subjects will be involved in the study for between 2 and 12 days. Two to three visits to the study doctor will be required. This study will compare the diagnostic results of Gadobutrol enhanced MRA images with MRA images taken without contrast agent using images from a CTA as the standard of reference, which may have been performed up to 60 days prior to enrolment. If a CTA has not been performed in this prior time period, a CTA is required for the study. MRA and CTA images will be collected for an independent review (blinded read).

Renal Artery Obstruction

Bayer317 participantsStarted May 2011

Tucson, Arizona, United States • Los Angeles, California, United States • Los Angeles, California, United States +67 more locations

COMPLETEDPhase 384 miles

Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections

NCT00466817

Cytomegalovirus (CMV) infection is known to cause hearing loss and mental retardation. The purpose of this study is to compare a 6-week course to a 6-month course of the drug valganciclovir in babies born with CMV to assess the safety and efficacy of this treatment. Participants will include 104 infants (30 days old or younger) born with CMV disease. All infants will take valganciclovir by mouth for 6 weeks. At the end of the 6 week period, subjects will be assigned by chance to receive either valganciclovir or placebo (inactive substance) to complete the 6 months of antiviral treatment. Patients will be followed for the study related evaluations of safety, changes to hearing, and developmental milestones for up to 2 years. Patients will be followed by telephone contact for an additional 3 years. Thus, participants may be involved in study related procedures for approximately 5 years.

Cytomegalovirus Infection

National Institute of Allergy and Infectious Diseases (NIAID)109 participantsStarted Jun 2008

Birmingham, Alabama, United States • Mobile, Alabama, United States • Little Rock, Arkansas, United States +45 more locations

TERMINATEDPhase 292 miles

Safety Study for the Treatment of Abdominal Aortic Aneurysms

NCT00610090

The primary study objective, at this time, is to follow out to 5 years post implant the safety of already enrolled subjects who were treated with the UniFit Aorto-uni-iliac (AUI) Endoluminal Stent Graft (the "study device") for the repair of abdominal aortic aneurysms (AAAs).

Abdominal Aortic Aneurysms

Duke Vascular, Inc.71 participantsStarted May 2007

Loma Linda, California, United States • Torrance, California, United States • Newark, Delaware, United States +16 more locations

TERMINATEDPhase 2118 miles

Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects

NCT00498914

A study in subjects with a type of B cell lymphoma (DLBCL)to evaluate the response rate, efficacy, safety and tolerability of YM155

Lymphoma, Large-Cell, DiffuseLymphoma, B-Cell Refractory

Astellas Pharma Inc41 participantsStarted Jun 2007

Beverly Hills, California, United States • Palo Alto, California, United States • Aurora, Colorado, United States +19 more locations

WITHDRAWNPhase 4118 miles

Clinical Evaluation of Placement of Radiofrequency-based Plasma Microdebridement in the Treatment Algorithm for Foot and Ankle Tendinosis and Plantar Fasciosis

NCT00420875

To determine the magnitude of improvement for pain and function symptoms over a two year period after enrollment into the registry study in patients presenting with chronic heel pain and receiving standard of care treatment. Standard of care will include traditional conservative care measures, ESWT, radiofrequency-based plasma microdebridement, scalpel debridement and/or surgical release.

Plantar Fasciosis, Achilles Tendinosis

ArthroCare CorporationStarted Jun 2007

Mesa, Arizona, United States • Santa Monica, California, United States • Oakwood, Georgia, United States

COMPLETEDPhase 2299 miles

A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS)

NCT01665391

The primary objectives of this trial are as follows: * to compare the achievement of a partial remission (PR) or complete remission (CR) in urinary protein: creatinine ratio (Up/c ratio) in patients treated with fresolimumab versus placebo * to compare the safety profile of patients treated with fresolimumab versus placebo The secondary objectives are as follows: * To compare the reduction in proteinuria in patients treated with fresolimumab versus placebo * To evaluate fresolimumab dose-dependent reduction in proteinuria * To compare the change in renal function (estimated glomerular filtration rate \[eGFR\]) in patients treated with fresolimumab versus placebo * To evaluate the multiple-dose pharmacokinetics of fresolimumab

Primary Focal Segmental Glomerulosclerosis

Genzyme, a Sanofi Company36 participantsStarted Aug 2012

Birmingham, Alabama, United States • Phoenix, Arizona, United States • San Francisco, California, United States +29 more locations

COMPLETEDPhase 2938 miles

LCZ696 Compared to Valsartan in Patients With Chronic Heart Failure and Preserved Left-ventricular Ejection Fraction

NCT00887588

The study will assess the effects of 36 weeks of treatment with LCZ696 compared to valsartan on N-terminal pro-Brain Natriuretic Peptide (NT-proBNP) in patients with chronic heart failure and preserved left-ventricular ejection fraction.

Chronic Heart Failure

Novartis Pharmaceuticals307 participantsStarted Nov 2009

Little Rock, Arkansas, United States • Chicago, Illinois, United States • Detroit, Michigan, United States +78 more locations

COMPLETEDPhase 3965 miles

A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.

NCT00391092

This 2 arm study will compare the efficacy and safety of Avastin plus Herceptin/docetaxel, versus Herceptin/docetaxel alone, in patients with HER2 positive locally recurrent or metastatic breast cancer who have not received prior chemotherapy for their metastatic disease. Patients will be randomized 1:1 to receive either Avastin (15mg/kg iv q3weeks) + Herceptin (8mg/kg iv loading dose and 6mg/kg iv q3weeks maintenance) + docetaxel (100mg/m2 iv q3weeks) or Herceptin + docetaxel alone. The anticipated time on study treatment is until disease progression, and the target sample size is 100-500 individuals.

Hoffmann-La Roche424 participantsStarted Sep 2006

Buenos Aires, Argentina • Córdoba, Argentina • La Plata, Argentina +86 more locations

COMPLETEDPhase 41183 miles

Induction-maintenance of Lopinavir/r in HIV-infected Subjects

NCT00159224

This study will assess the safety, tolerability and antiviral activity of a simplified PI-based treatment regimen (Kaletra,ä) compared to conventional HAART regimens in patients infected with HIV-1 who are on their first boosted-PI antiretroviral treatment regimen. The potency of the antiviral activity of Kaletra has been clearly demonstrated in a wide spectrum of patients in a number of different clinical trials.6-9 The durable viral suppression seen after 4 years of therapy10 proves that it can provide effective, long-term treatment for people with HIV-1. Data from one of these trials (M97-720),6 an ongoing Phase II study of lopinavir/ritonavir in combination with NRTIs suggests there may be a role for monoclass therapy with Kaletra in the treatment of HIV-1-infection.

Fundación Huésped100 participantsStarted Apr 2005

Buenos Aires, Argentina • Buenos Aires, Argentina • Vancouver, British Columbia, Canada +1 more locations

PreviousPage 598 of 734Next

Diabetes

in San Diego

Heart Diseasein San Diego